Nov 28th, 2022
ALZpath Inc., an Alzheimer’s Disease Diagnostics and Patient Services Company Announces Novel Validated and Scalable Assay for Detection of Phosphorylated Tau 217 in Blood
Carlsbad, Calif., Nov. 28, 2022 – ALZpath, Inc. announced today the launch of its first diagnostic assay for detection of phosphorylated tau 217 (pTau217) in blood. pTau217 is widely considered to be one of the leading transformative Alzheimer’s disease (AD) diagnostic biomarkers by enabling earlier and more accurate AD diagnoses, better stratifying patients for clinical trials, and improving patient outcomes and care. ALZpath is actively working with a wide network of early access collaborators to further develop clinical evidence across diverse patient populations.
ALZpath’s pTau217 assay in blood offers a simple and cost-effective approach to diagnosis, which is less invasive than current testing methods. The ALZpath pTau217 assay is validated and available now for research studies and clinical trials and will be available for clinical use as a laboratory developed test in early 2023.
“This marks a major milestone in the availability of scalable accessible tools for research, clinical trials, and clinical use,” said Andreas Jeromin, PhD, Chief Scientific Officer at ALZpath.
ALZpath was founded in 2020 and is a privately held company. The company’s mission is to transform the Alzheimer’s disease ecosystem by advancing patient care, clinical trials, and research by integrating novel blood-based and other biomarkers, clinical assessment tools, and care solutions. ALZpath has assembled an experienced management team and world-renowned advisory board.
ALZpath will present analytical and initial clinical performance data for this novel accessible and scalable assay for pTau217 in blood at the Clinical Trials in Alzheimer’s Disease (CTAD) Conference Nov. 29 – Dec. 2, 2022, in San Francisco. The ALZpath leadership team will be available for meetings and discussion during this time.
About ALZpath
ALZpath is a leading provider of innovative diagnostic solutions for Alzheimer’s disease. With the novel ALZpath pTau217 Assay, ALZpath is transforming Alzheimer’s disease diagnosis and monitoring, providing accurate and accessible tools for researchers and healthcare professionals worldwide.
Media Contact
Andreas Jeromin
Chief Scientific Officer, PhD., MD
ALZpath
Andreas@alzpath.bio
Investor Contact
Jacob Hunter
Vice President, Business and Corporate Development
ALZpath, Inc.
jacob@ALZpath.bio
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on ALZpath’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause ALZpath’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in ALZpath’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, ALZpath assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
